Loading…
www.dashpct.com was cited for introducing unapproved and misbranded semaglutide drug products into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(a), 301(d), 503(b), and 505(a)). The company was selling these drugs over the internet to U.S. consumers without prior FDA approval, failing to meet regulatory safeguards designed to ensure drug safety and effectiveness. The FDA warned that unapproved drugs bypass critical oversight and may be contaminated, counterfeit, contain inconsistent active ingredient amounts, or contain entirely different ingredients, posing inherent risks to consumers. The FDA requested that the company immediately cease offering these unapproved and misbranded drugs for sale to U.S. consumers.